U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Grand Rounds
  1. About Science & Research at FDA


FDA Grand Rounds Image


The FDA Grand Rounds is an educational presentation that is webcast monthly to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute educational presentation is followed by questions from the audience. You can also view the presentation under Past Grand Rounds following the live webcast. #FDAGrandRounds.

The next FDA Grand Rounds is scheduled for December 10, 2020. (Webcast only)

For more information and to register:

FDA Grand Rounds: Assessment of Safety and Efficacy of Fecal Microbiota for Transplantation Products

Thursday, December 10, 2020
12:00 p.m. - 1:00 p.m. EST

About the Speaker:

Paul Carlson, PhD
Principal Investigator, Laboratory of Mucosal Pathogens and Cellular Immunology
Office of Vaccines Research and Review, CBER, FDA

Dr. Carlson received his Ph.D. from the University of Pittsburgh and performed postdoctoral research at the University of Michigan in the laboratory of Phil Hanna. Since starting his laboratory at FDA in 2015, Dr. Carlson’s research has focused on infections caused by the enteric pathogens Clostridium difficile and Vancomycin resistant Enterococcus (VRE) species. Laboratory projects include researching mechanisms of C. difficile pathogenesis, development of genetic tools to study C. difficile, host response to C. difficile, the role of the host microbiota in C. difficile colonization resistance, the influence of the host immune system on the microbiome, safety of Fecal Microbiota Transplantation products, and bacteriophage therapy against VRE. Dr. Carlson is the former co-chair of the FDA microbiome working group and the Joint Agency Microbiome (JAM) working group, as well as a former member of the Microbiome Interagency Working Group (MIWG). His regulatory responsibilities include product review for fecal microbiota transplantation (FMT), defined live biotherapeutic products, and bacteriophage therapies.

About the Presentation:

This presentation provides an overview of the FDA’s research on how Fecal Microbiota Transplantation (FMT) is a novel treatment being assessed for use in the treatment of many, highly diverse conditions ranging from infections to inflammatory bowel diseases and even neurological disorders. Additionally, we have been working to understand the impact of the COVID-19 pandemic on this class of products as SARS-CoV-2 viral RNA has been detected in stool. Detail of these efforts, including development and validation of a SARS-CoV-2 stool test, assessment of clinical stool samples and preliminary animal studies will be discussed along with the impact of this work and the pandemic overall on the safety and availability of FMT products.

Past Grand Rounds






Resources For You

Sub-Topic Paragraphs

Latest From the Commissioner

Dr. Hahn’s Remarks to the Meeting of the Regulatory Affairs Professionals Society (RAPS) - 11/17/2020

Nov 19

Remarks by Dr. Hahn to the Friends of Cancer Research Annual Meeting - 11/13/2020

Nov 13

Dr. Hahn's Remarks to the GRx+Biosims 2020 Virtual Conference - 11/09/2020

Nov 09

Remarks by Frank Yiannas at the International Association for Food Protection 2020 Annual Meeting - 10/27/2020

Oct 27

Remarks for the Global Pharmaceutical Manufacturing Leadership Forum - 11/01/2020

Nov 01

Dr. Hahn's Remarks to FDA's Disability Awareness Roundtable - 10/29/2020

Oct 29

FDA Presentation: American Public Health Association's 2020 Virtual Annual Meeting - 10/26/2020

Oct 28

Dr. Hahn's Remarks to the Intergovernmental Working Meeting on Drug Compounding - 10/27/2020

Oct 27

Subscribe to FDA Grand Rounds email updates

The latest information on the FDA Grand Rounds

Back to Top